AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Receives “Buy” Rating from Piper Jaffray Companies
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “buy” rating restated by equities researchers at Piper Jaffray Companies in a research report issued on Thursday. They presently have a $3.50 target price on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 22.38% from the stock’s current price.
Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Monday, July 24th. FBR & Co reiterated a “buy” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research report on Friday, June 30th. Finally, ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 2.85 on Thursday. The company’s 50 day moving average is $2.38 and its 200-day moving average is $1.12. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $3.19. The company’s market capitalization is $314.53 million.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/10/aveo-pharmaceuticals-inc-nasdaqaveo-receives-buy-rating-from-piper-jaffray-companies.html.
Institutional investors have recently bought and sold shares of the company. Clear Harbor Asset Management LLC acquired a new position in AVEO Pharmaceuticals during the second quarter worth approximately $289,000. Paloma Partners Management Co acquired a new position in AVEO Pharmaceuticals during the first quarter worth approximately $184,000. UBS Oconnor LLC acquired a new position in AVEO Pharmaceuticals during the first quarter worth approximately $291,000. Perceptive Advisors LLC raised its position in AVEO Pharmaceuticals by 64.3% in the first quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 2,000,000 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock worth $1,482,000 after buying an additional 148,500 shares in the last quarter. 51.04% of the stock is currently owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.